SEOUL, South Korea, May 30, 2025 /PRNewswire/ — CJ Olive Young, Korea’s leading beauty and health retailer, has officially launched the OLIVE YOUNG SUMMER SALE on its international mobile app and website. Formerly known as the “Big Bang Sale,” this major promotion is now part of Olive Young’s newly rebranded seasonal campaign, held four times a year.

From trending K-beauty must-haves in Korea to viral social media favorites, shoppers can enjoy exclusive deals during this one-week event held each season. The OLIVE YOUNG SUMMER SALE runs from May 31 to June 6.

This summer’s sale spotlights seven “Hero Brands”, all beloved by K-beauty fans around the world (listed in alphabetical order): Anua, BIOHEAL BOH, CLIO, MEDIHEAL, ROUND LAB, Torriden, and UNOVE.

Customers in the U.S. and select regions can enjoy free shipping on orders over $60, and first-time buyers receive a 15% welcome coupon on their initial purchase. Search for “Olive Young Global” to download the app or visit the website to start shopping. With discounts of up to 77%, the event offers global customers the chance to explore the most sought-after Korean beauty products at unbeatable prices.

CJ Olive Young operates the Olive Young Global app and website, serving customers in over 150 countries with a growing community of 2.4 million members. With more than 10,000 products from Korea’s leading beauty brands, Olive Young brings the best of K-beauty to one convenient destination.

Visit https://global.oliveyoung.com/ to explore the OLIVE YOUNG SUMMER SALE lineup.

BEIJING, May 30, 2025 /PRNewswire/ — Finding Answers in China from China.org.cn:

How did a bottle of chili paste from Sri Lanka make its way overseas and go viral in a Chinese live streaming? And how did a traditional handmade stool help revive the rural economy in Sri Lanka? What made a live streaming that sold out its inventory in just 3 minutes convince Sri Lankan entrepreneur Chiranjaya Udumullage of the huge potential and strong vitality of the Chinese market?

Devinder Kumar, a host from CICG Europe-Asia, enters the live streaming room, eager to find out how Chiranjaya Udumullage is promoting business and sale for his hometown’s quality products.

Sold out in 3 minutes! How a Sri Lankan streamer masters Chinese e-commerce live streaming?
https://youtu.be/TH78bxKCIJk

SHENZHEN, China, May 30, 2025 /PRNewswire/ — Elegoo, a rapidly developing brand in global smart manufacturing, has expanded its corporate social responsibility (CSR) programs with the launch of ELEGOO Empowers, a new initiative promoting social inclusion, STEM education, and equal opportunity through 3D printing technology. The launch marks a key milestone as the company celebrates its 10th anniversary.

This initiative builds on and unifies Elegoo’s ongoing CSR efforts under a stronger, more cohesive framework, including three key programs:

ELEGOO Gives A Hand: Harnessing 3D printing to deliver practical, reliable solutions for people and animals in need, while inspiring creativity and joy among users worldwide. From prosthetics to harnesses and assistive devices, Elegoo develops these in collaboration with partners like 3D Pets. More heartwarming projects are on the way.

ELEGOO With Her: Encouraging more women to develop their 3D printing skills through hands-on workshops and a supportive community. As the first 3D printer manufacturer to take meaningful steps toward addressing the gender gap, Elegoo is creating a more inclusive space where women can learn, connect, and build projects that expand the possibilities of 3D printing and create real-world impact. Projects by current participants will be showcased this June.

ELEGOO In Action: Promoting STEM education by providing 3D printers, supporting learning initiatives, and offering hands-on resources to schools, libraries, and student clubs worldwide, helping young creators explore robotics, model car building, and other real-world applications. Since last year, Elegoo has partnered with over 120 schools and student teams around the world.

“With ELEGOO Empowers, we’re taking that spirit beyond the desktop to help build a more inclusive and connected world,” said Chris Hong, Founder and CEO of Elegoo. “Inspired by the voices of our users, we will continue on this path and warmly invite more partners to join us in making this technology more meaningful and accessible.”

As 3D printing continues to evolve, Elegoo has spent the past 10 years leveraging the technology to empower users around the world. Many have shared their “ELEGOO moments” of giving back and helping others. Looking ahead, Elegoo is committed to making 3D printing more accessible and advancing its ESG efforts to create a more sustainable and inclusive future.

About Elegoo

Founded in 2015, Elegoo is a rapidly developing brand in the global smart manufacturing industry, specializing in R&D, manufacturing, and sales of consumer-grade 3D printers, laser engravers, STEM kits, and other smart technology products. Located in Shenzhen, the Silicon Valley of China, the company has sold millions of products across more than 90 countries and regions. In 2024, the company’s total sales revenue surpassed 200 million USD, with more than 800 employees and nearly 30,000 square meters of office and manufacturing area. With a focus on programming and 3D printing technology, Elegoo provides unique and smart creation spaces for diverse consumers to enhance personalized experiences.

YONGIN, South Korea, May 30, 2025 /PRNewswire/ — GC Biopharma, a South Korean pharmaceutical company, announced that the Phase 3 clinical trial results for Hunterase (idursulfase beta), its investigational drug for Hunter Syndrome (MPS II), have been published in Genetics in Medicine, an SCIE-indexed journal.

Conducted at Samsung Medical Center, the Phase 3 clinical trial enrolled 24 newly diagnosed Hunter Syndrome patients with no prior treatment. It evaluated the efficacy and safety of Hunterase over a one-year treatment period.

Hunter Syndrome is a rare genetic disorder caused by a deficiency of iduronate-2-sulfatase (IDS), an enzyme critical for glycosaminoglycan (GAG) catabolism. This deficiency leads to the progressive accumulation of GAGs in various organs and tissues, resulting in multisystemic dysfunction, including joint stiffness and hepatosplenomegaly.

The clinical trial results demonstrated that Hunterase significantly enhanced functional mobility, reduced urinary GAG concentrations, and markedly alleviated hepatosplenomegaly.

In the 6-Minute Walk Test (6-MWT), the primary endpoint of the study, patients treated with Hunterase walked an average of 62.2 meters more after treatment. This improvement was more than eight times greater compared to the placebo group, which saw an average increase of just 7.3 meters.

The 6-MWT measures the distance a patient can walk on a flat surface within 6 minutes. It is a widely used clinical measure for evaluating functional mobility, cardiopulmonary function, muscle strength, and overall physical health. In the context of Hunter syndrome, it serves as a standardized and meaningful indicator of disease progression and quality of life.

In addition to the primary endpoint, the study also achieved positive outcomes in secondary endpoints, including changes in urinary total glycosaminoglycan (GAG) levels, as well as heparan sulfate (HS) and dermatan sulfate (DS) levels. The GAG levels decreased by 71%, while HS and DS levels decreased by 89% and 88%, respectively. Moreover, liver and spleen volumes were reduced by 27% and 26%, respectively, demonstrating the drug’s effectiveness in addressing organ enlargement commonly associated with the disease.

Hunterase also demonstrated a favorable safety profile. Most adverse events were mild or moderate, and no patients discontinued treatment due to side effects. Notably, only 19% of the patients had neutralizing antibodies detected three or more consecutive times, which is significantly lower than the 62.5% observed with the existing treatments. This suggests that Hunterase may offer a more sustained therapeutic effect compared to other currently available therapy.

“This clinical trial is especially meaningful as it represents the first Phase 3 study in Asian patients to validate the clinical efficacy of Hunterase”, said Professor Young Bae Sohn of Ajou University School of Medicine and Ajou University Hospital, the journal’s first author. “The results showed significant clinical improvement not only in metabolic markers but also in organ size normalization and restoration of physical mobility.”

“We are thrilled to publish our encouraging phase 3 clinical trial results”, stated Jae Uk Jeong, Head of R&D at GC Biopharma. “Hunterase, developed in Korea using our proprietary technology, has the potential to significantly improve the lives of patients with Hunter syndrome.”

Hunter Syndrome is an X-linked lysosomal storage disorder, affecting approximately 1 in 100,000 male births. In severe cases, the patients experience early death before they reach adulthood, highlighting the need for early diagnosis and treatment. Currently, two treatments are widely available worldwide for Hunter Syndrome: GC Biopharma’s Hunterase and Takeda’s Elaprase.

About GC Biopharma

GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo™(intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit https://www.gcbiopharma.com/eng/

This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma’s management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.

GC Biopharma Contacts (Media)

Sohee Kim
shkim20@gccorp.com

Yelin Jun
yelin@gccorp.com

Yoonjae Na
yjy6520@gccorp.com

HONG KONG, May 30, 2025 /PRNewswire/ — As the global gaming population surpasses 3 billion and mobile esports continues to rise, gamers’ demands for immersive experiences are evolving rapidly. Gaming is no longer confined to simple environments—it now extends across diverse scenarios where seamless device collaboration is essential. Players are no longer content with traditional gaming tools; they seek deeper immersion, longer battery life, and a balance between high-performance gameplay and creative productivity.

This shift is driving mobile brands away from a purely hardware-centric race toward comprehensive ecosystem development. Infinix‘s response goes beyond building yet another uninspiring gaming system—it’s about creating a true digital playground.

GT VERSE was born from this idea: a mobile gaming space that’s innovative, dynamic, and fun. Like stepping into a theme park, each product—from the GT 30 Pro smartphone and XPAD GT tablet to the GTBUDS 4 earbuds, GTPOWER power bank, and magnetic cooling case—fits together like building blocks, forming a seamless immersive system. Devices work in sync, staying cool and stable under pressure, letting you switch effortlessly from gameplay to content creation.

Immersion Beyond the Screen

Within the GT VERSE ecosystem, the XPAD GT is much more than a supersized phone. It is the kind of device users will hesitate to turn off once it is powered on: a 13-inch 2.8K high-resolution display, 144Hz refresh rate, eight-speaker stereo system, and Snapdragon 888 chipset—all configured with immersion in mind.

For mobile gamers, smartphones offer unmatched convenience—allowing users to team up with friends and join a match at any time, from virtually any location. Personal computers, on the other hand, deliver a rich and fully immersive gaming experience. The XPAD GT strikes a perfect balance between the two. It delivers the satisfaction of a large-screen view while remaining lightweight and portable.

It is also a powerhouse in both performance and endurance. Equipped with a 10,000mAh battery and 33W fast charging, along with a VC liquid cooling system, the device allows users to stream content or play ranked matches for extended periods without overheating.

However, what truly distinguishes the XPAD GT is not just its hardware. Infinix has integrated intelligent features at the system level, such as the Folax AI Assistant and seamless cross-device collaboration. Receive a game invitation on your phone? Switch to the larger screen with a single tap for a more immersive experience. The device also supports keyboards and styluses, making it well-suited for light productivity tasks, emails, or quick video edits following a gaming session.

Far beyond a conventional tablet, the XPAD GT provides access to the GT Playground—a dynamic space where gameplay and reality intersect with fluid precision.

Gear That Powers Every Move

In the GT VERSE playground, every accessory plays a critical role in delivering the immersive experience:

GTBUDS 4 – Featuring 12.4mm drivers and 30dB active noise cancellation, these earbuds eliminate external distractions to provide pure sound immersion. Four-microphone AI noise reduction and Bluetooth 6.0 ensure crystal-clear and smooth communication. With dynamic lighting effects, they serve as both a high-performance audio solution and a bold fashion statement.

GTPOWER – This 55W fast-charging power bank delivers universal compatibility across smartphones, tablets, and laptops. Equipped with a digital display and an integrated braided Type-C cable, it serves as a dependable power source while on the move.

Case & Cooling Fan – Designed to support uninterrupted gaming while charging, this accessory strikes a balance between comfort and performance. Magnetic snap-on cooling, RGB lighting, and efficient heat dissipation work together to keep the device cool and lag-free during high-intensity sessions.

Together, this lineup transforms the GT VERSE into a truly portable mobile playground. Whether the priority is immersion, endurance, or seamless connectivity, GT VERSE equips gamers with a comprehensive arsenal—prepared for action in any scenario.

An Ecosystem Built to Win

As the boundaries between gaming, creativity, and mobile productivity continue to blur, GT VERSE offers a focused, all-in-one solution tailored to this convergence.

Every component is engineered to provide real-world value—not only in terms of performance, but also adaptability. Whether during moments of deep focus or while in transit, GT VERSE remains in step with users’ evolving needs.

Pricing and availability:
The Infinix XPAD GT will be available in Stellar Grey, with memory of 256+8GB. Pricing will vary by region, with full details to be announced at launch.

About Infinix
Established in 2013, Infinix is an innovation-driven brand dedicated to delivering cutting-edge technology, bold design, and outstanding performance. The brand provides smart, enjoyable mobile experiences that enhance everyday life. Beyond smartphones, Infinix has expanded its portfolio to include TWS earbuds, smartwatches, laptops, tablets, smart TVs, and more—building a comprehensive ecosystem of smart devices. Currently, Infinix products are available in over 70 countries and regions worldwide, including Africa, Latin America, the Middle East, South Asia, and Southeast Asia.

For more information, please visit: www.infinixmobility.com/